Moy, B., Rumble, R. B., Come, S. E., Davidson, N. E., Di Leo, A., Gralow, J. R., Hortobagyi, G. N., Yee, D., Smith, I. E., Chavez-MacGregor, M., Nanda, R., McArthur, H. L., Spring, L., Reeder-Hayes, K. E., Ruddy, K. J., Unger, P. S., Vinayak, S., Irvin, W. J., Armaghani, A., Danso, M. A., Dickson, N., Turner, S. S., Perkins, C. L., & Carey, L. A. (2021). chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor–Negative: ASCO Guideline Update. Journal of clinical oncology, 39(35), 3938–3958. http://access.bl.uk/ark:/81055/vdc_100150611153.0x00002e